Dyskinetic and Spastic Movement Disorders & Medical Marijuana: Pennsylvania Qualifying Condition Guide

Dyskinetic and spastic movement disorders are a group of neurological conditions involving involuntary movements or increased muscle tone that leads to stiffness and impaired mobility. Pennsylvania recognizes these disorders as a qualifying condition for its medical marijuana program. If you or a loved one is living with a movement disorder, Compassionate Certification Centers can help you understand your options and determine whether certification may be appropriate as part of your neurological care.

This is a broad qualifying category that covers a range of distinct neurological conditions with very different causes, presentations, and cannabis research evidence. It is important to evaluate the evidence specific to each condition rather than assuming uniform results across this category, a treatment that shows promise for one movement disorder may show no benefit, or even worsen symptoms, in another.

BOOK NOW

Diagnosis depends heavily on the specific disorder suspected, but generally involves:

• Detailed neurological examination assessing movement patterns, muscle tone, and reflexes
• Clinical history, including age of onset, family history, and medication history (especially levodopa exposure for suspected LID)
• Standardized rating scales specific to each disorder (e.g., Unified Parkinson’s Disease Rating Scale for LID, Yale Global Tic Severity Scale for Tourette syndrome, Burke-Fahn-Marsden scale for dystonia)
• Genetic testing, where applicable (e.g., for Huntington’s disease)
• Brain imaging (MRI) to rule out structural causes or identify underlying CNS pathology
• In some cases, referral to a movement disorder specialist (a neurologist with subspecialty training)

BOOK NOW

Because this qualifying condition spans several distinct disorders, the research evidence is best understood disorder by disorder rather than as a single category. Overall randomized controlled trial evidence in this area is more developed than in many other conditions but the findings are decidedly mixed, with several well-designed trials showing no benefit and at least one showing a cannabinoid worsening symptoms. This honest, mixed picture is presented in full below. This section is informational only and does not constitute medical advice.

1. Levodopa-Induced Dyskinesia (Parkinson’s Disease): Mostly Negative Trial Results

A 2022 systematic review of randomized controlled trials in movement disorders found that of three RCTs examining levodopa-induced dyskinesia as a primary outcome, only one (using the synthetic cannabinoid nabilone) showed a measurable reduction, while studies using whole-plant oral cannabis extract found no objective or subjective improvement in dyskinesia. A separate 2020 systematic review concluded that the positive effects on motor symptoms reported in small, uncontrolled studies have not been confirmed in the few and small RCTs available, and stated there is insufficient evidence to support cannabis use in Parkinson’s disease clinical practice. The American Academy of Neurology’s evidence-based guideline on medical marijuana similarly concluded that oral cannabis extract is “probably ineffective” for treating levodopa-induced dyskinesia.

2. Dystonia: Negative Trial Evidence

A randomized, double-blind, placebo-controlled crossover trial using the synthetic cannabinoid nabilone in patients with generalized and segmental primary dystonia found no significant reduction in dystonia symptoms compared to placebo. This remains one of relatively few controlled trials specific to dystonia, and the negative result is an important part of the evidence picture for this category.

3. Tourette Syndrome & Tic Disorders: The Most Consistently Positive Signal

Tic disorders represent the area within this category with the most consistent, though still limited, positive RCT evidence. Several small randomized controlled trials using THC have found statistically significant reductions in tic severity compared to placebo, and a 2023 double-blind crossover trial of combined THC and CBD in adults with Tourette syndrome (published in NEJM Evidence) similarly found evidence of benefit. A 2023 systematic review concluded that despite encouraging signals, a Cochrane review on this topic found that definitive conclusions cannot yet be drawn due to the small number of patients studied and short trial durations, and called for larger, longer trials. Notably, not all studies have replicated this benefit — one real-world observational study of cannabis use in Tourette patients found no statistically significant improvement in tic frequency or severity, illustrating how findings can vary between controlled trial settings and real-world use.

4. Huntington’s Disease (Chorea): Caution Warranted

Evidence for cannabinoids in Huntington’s disease is limited and includes an important cautionary finding. While one small RCT using nabilone found some symptom relief, a separate published case study found that nabilone actually increased choreatic (involuntary movement) symptoms in a Huntington’s patient. This conflicting evidence underscores why cannabis use for Huntington’s-related chorea should only be considered under close neurological supervision, with careful individual monitoring for symptom worsening.

5. Why the Evidence Is So Mixed: A Note on Trial Design

Across this entire category, researchers consistently note a pattern: observational and uncontrolled studies tend to report more favorable results than rigorous randomized controlled trials. This is a common and well-recognized phenomenon in clinical research generally, often attributed to placebo effects, reporting bias, and the absence of blinded comparison groups in observational data. It reinforces why RCT evidence — even when it shows no benefit or mixed results — should be weighted more heavily than patient-reported or observational accounts when making treatment decisions.

BOOK NOW

Pennsylvania recognizes dyskinetic and spastic movement disorders as a qualifying condition. The certification process with Compassionate Certification Centers is straightforward:

Step 1: Register over the phone or online, next-day appointments are often available.
Step 2: Meet with a certified medical marijuana physician who will review your specific movement disorder diagnosis, current treatment, and symptom profile to determine whether certification is appropriate.
Step 3: Receive your Pennsylvania medical marijuana card and begin purchasing from licensed dispensaries.

Because the evidence and risks vary significantly across the conditions in this category, our physicians are experienced in working alongside neurologists and movement disorder specialists to ensure any cannabis-based approach is appropriate for your specific diagnosis and is coordinated with your existing treatment plan.